HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kimzey, S. L. Articles by Green, J. M. Search for Related Content PubMed PubMed Citation Articles by Kimzey, S. L. Articles by Green, J. M.

Requirement for CD28 in the Effector Phase of Allergic Airway Inflammation¹

Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO 63110

Central to the pathogenesis of allergic airway inflammation are the activation and differentiation of T lymphocytes. This process requires the participation of the CD28 costimulatory receptor. Blockade of CD28 has been demonstrated to prevent inflammation and airway hyperreactivity in a murine model of asthma. Whether this is due specifically to defects in initial T cell activation or whether effector responses are also impaired has not been determined. Using adoptive transfer studies of Ag-specific lymphocytes, we demonstrate that CD28 has a critical role in both the induction and effector phase of allergic airway inflammation. Transfer of in vitro activated and Th2-differentiated Ag-specific lymphocytes from wild-type hosts restored inflammation, but not tissue eosinophilia in CD28-deficient recipients. Furthermore, similarly activated and differentiated CD28-deficient lymphocytes were ineffective at mediating inflammation in wild-type recipients. Secondary cytokine and proliferative responses of activated Th2 cells were highly dependent on CD28 in vitro. Moreover, eosinophil recruitment to both the lung and peritoneum is impaired by the lack of CD28, suggesting a generalized defect in the ability of eosinophils to accumulate at sites of inflammation in vivo. These data identify a novel role for CD28 in the effector phase of allergic airway inflammation and suggest that inhibition of this pathway may be a useful therapeutic intervention in previously sensitized individuals.

This article has been cited by other articles:

				L. Chen, W. Cheng, P. Shivshankar, L. Lei, X. Zhang, Y. Wu, I-T. Yeh, and G. Zhong Distinct Roles of CD28- and CD40 Ligand-Mediated Costimulation in the Development of Protective Immunity and Pathology during Chlamydia muridarum Urogenital Infection in Mice Infect. Immun., July 1, 2009; 77(7): 3080 - 3089. [Abstract] [Full Text] [PDF]

				L. F. Dodson, J. S. Boomer, C. M. Deppong, D. D. Shah, J. Sim, T. L. Bricker, J. H. Russell, and J. M. Green Targeted Knock-In Mice Expressing Mutations of CD28 Reveal an Essential Pathway for Costimulation Mol. Cell. Biol., July 1, 2009; 29(13): 3710 - 3721. [Abstract] [Full Text] [PDF]

				C. Deppong, J. M. Degnan, T. L. Murphy, K. M. Murphy, and J. M. Green B and T Lymphocyte Attenuator Regulates T Cell Survival in the Lung J. Immunol., September 1, 2008; 181(5): 2973 - 2979. [Abstract] [Full Text] [PDF]

				L. D. Friend, D. D. Shah, C. Deppong, J. Lin, T. L. Bricker, T. I. Juehne, C. M. Rose, and J. M. Green A dose-dependent requirement for the proline motif of CD28 in cellular and humoral immunity revealed by a targeted knockin mutant J. Exp. Med., September 4, 2006; 203(9): 2121 - 2133. [Abstract] [Full Text] [PDF]

				C. Deppong, T. I. Juehne, M. Hurchla, L. D. Friend, D. D. Shah, C. M. Rose, T. L. Bricker, L. P. Shornick, E. C. Crouch, T. L. Murphy, et al. Cutting Edge: B and T Lymphocyte Attenuator and Programmed Death Receptor-1 Inhibitory Receptors Are Required for Termination of Acute Allergic Airway Inflammation J. Immunol., April 1, 2006; 176(7): 3909 - 3913. [Abstract] [Full Text] [PDF]